geht hier was

Seite 51 von 55
neuester Beitrag: 17.06.21 19:53
eröffnet am: 15.03.12 22:06 von: toni1111 Anzahl Beiträge: 1351
neuester Beitrag: 17.06.21 19:53 von: Lerner84 Leser gesamt: 315463
davon Heute: 838
bewertet mit 4 Sternen

Seite: 1 | ... | 48 | 49 | 50 |
| 52 | 53 | 54 | ... | 55   

23.04.21 22:49

228 Postings, 227 Tage BUT73Schöne PR

Jetzt ist das Medi auch endlich im Weissen Haus angekommen und wird dazu noch durch den Direktor den National Institute of Allergy and Infectious Diseases (NIAID) in seiner Präsentation  zur Covidbekämpfung erwähnt.

Aviptadil hat durch die Aufnahme in den neuen von der US Regierung finanzierten Studien die Anerkennung erhalten, die es verdient und zusätzlich  den Ritterschlag bekommen. Wenn das keine guten Aussichten auf die lang ersehnte Notfalzulassung sind, dann esse ich einen Besen, oder auch zwei.

Ich wünsche allen Investierten viel Glück und weiterhin einen langen Atem und Durchhaltevermögen. Wir haben es schon mal bis zu den Startblöcken geschafft.
 

23.04.21 23:51

665 Postings, 525 Tage IneosDieser Link sollte funktionieren ! Minute 17 :-)

24.04.21 00:45

228 Postings, 227 Tage BUT73Fauci video

bei circa Minute 16-17 spricht er über zyesami (Aviptadil - RLF100)  

24.04.21 07:59

665 Postings, 525 Tage IneosInterview Ram :-)

The Market logo
Interview
Relief Therapeutics: «Our drug could generate hundreds of millions of dollars per year»

Raghuram Selvaraju, Chairman of Relief Therapeutics, comments on the newly gained billion-dollar valuation of the small Swiss biotech company and explains the approval chances for its drug Aviptadil to treat Covid-19.
Michael Griesdorf und Ruedi Keller
07.08.2020, 22.34 Uhr
«Our study aimed at patients who are severely ill due to Covid-19 has registrational quality. If it would be successful it could be the basis for a FDA approval of our drug», says Raghuram Selvaraju, Chairman of Relief Therapeutics.
«Our study aimed at patients who are severely ill due to Covid-19 has registrational quality. If it would be successful it could be the basis for a FDA approval of our drug», says Raghuram Selvaraju, Chairman of Relief Therapeutics.
ZVG

Deutsche Version

Few people knew about Relief Therapeutics 📈 a few months ago. With a market capitalisation of around CHF 2 million, the shares belonged to the segment of so-called penny stocks - future uncertain. However, since the small biotech company announced that it might have a drug for the treatment of Covid-19 patients in its pipeline, investor interest has been growing inexorably.

«It is very challenging to treat this disease and rare to identify a therapy that actually can have an impact», says Raghuram «Ram» Selvaraju, Chairman of Relief Therapeutics in this interview with The Market/NZZ. There is now first evidence that Relief's drug is working. «That is driving the attention on our stock now», Selvaraju says.

Since the beginning of the year, the Relief shares have jumped over 60,000%. The company, which was floated on the Swiss stock exchange through a merger with Therametrics (formerly MondoBiotech), has grown to a market capitalization of well over CHF 1 billion. This week alone, the stock price gained over 2,000%: «Our drug could generate hundreds of millions of dollars per year», says Selvaraju.

Ram, at the beginning of the year, the market capitalization of Relief stood at merely CHF 2 mio. In the past week, the value has grown to more than CHF 1bn. This surge was driven by hopes that Relief has a drug candidate – RLF-100 (Aviptadil) – that showed in first clinical trials a rapid recovery from respiratory failure in the most critically ill patients with Covid-19. In addition, independent researchers have reported that Aviptadil blocked replication of the Sars-CoV-2 in human lung cells and monocytes. How does that feel?

I believe the attention we are getting now is a function of the severity and the global nature of the Covid-19 pandemic. And, it is a function of the fact that we have been fortunate enough to move a clinical program ahead very quickly: We have now started to see evidence that the drug is working. Many other people have tried things in Covid-19 and didn't get very far. That reflects, how challenging it is to treat this disease and how rare it is to identify a therapeutic that actually can have an impact. That is driving the attention on our stock now.

Relief is a small Swiss based biotech company and has largely remained under the radar so far. It has no CEO, you as the Chairman have a full-time job being a Healthcare Analyst at the US Investment firm H.C. Wainwright & Co. How is Relief Therapeutics run and how many employees work at the company?

Right now, the board of directors manages the company and oversees the decision making. We have an US development company, NeuroRx, that administers the clinical development program for our drug RLF-100. NeuroRx is handling the day to day operations from a clinical development perspective. Before we started the current program, we have been identifying ways to bring Aviptadil forward for other indications. Back then, we did not have any clue that Covid-19 existed or that it will turn out to be such a global problem – or that our drug would be a potential solution for that problem.

In order to justify the current market value well in excess of CHF 1 bn, Relief must be building up a profit potential of more than CHF 100 mio. per year that is realizable for at least 10 years in a row. Is this realistic?

That is very realistic. The Covid-19 pandemic has officially infected 19 Mio. people worldwide. However, that is a gross underestimate of the actual figure. The official numbers reflect only how much testing is done. The number of people that get sick and face respiratory difficulties is somewhere between one and five percent. That might not sound like an impressive statistic. But given the numbers of tens of millions of people infected, this is a sizable population, particularly if you look at the relative benefit of our drug: If it saves lives, how do you put a price on that?

What are your revenue expectations?

If the drug is approved there are three scenarios: Assume it is approved in an environment in which Covid-19 disappears very quickly. I think we can almost totally rule out that scenario. It looks more like that the problem is actually getting worse. The second scenario is an approval for the drug while the disease persists for several more years, but eventually goes away. In that context, we think it is quite likely that peak annual sales of RLF-100 would be much higher than the CHF 100 Mio. annual figure mentioned in your question. The pricing depends on the competitive landscape and the question if there are effective vaccines available etc. In this base scenario and with effective vaccines available, it will take several years to deploy them. Our drug would have four to six years of potential deployment for those patients who get severely ill – and it could generate hundreds of millions of dollars per year during that timeframe.

And the third scenario?

So far no one has developed an effective vaccine against any coronavirus. We have to face the possibility that we will never get a vaccine that provides a durable protection against Covid-19. We have to recognize that this is the way corona viruses behave or how our immune system works. There is also a possibility that there is no effective vaccine. Social distancing over a long period of time is not practical as it would kill the economy. There would come a time when everyone would reach a level of comfort with some degree of risk tolerance and the disease would burn on.

Who owns the rights on Aviptadil?

Relief owns the patents on Aviptadil that are currently valid in the US and in Europe. In both jurisdictions we have orphan drug status, too.

Together with its partner NeuroRx, Relief is currently conducting several studies in Israel and the US on Aviptadil for the treatment of Covid-19 patients. Are these studies relevant for approval?

Let’s focus on the US: That is a Phase IIb/III trial that is aimed at patients who are severely ill because of the consequences of Covid-19. Assuming we have positive, statistically significant data, we would be in a position to go to the FDA and ask for approval. There is also a potential way to get approval sooner: This is by presenting the FDA clear evidence that the drug is therapeutically meaningful effective in a so-called compassionate access program. Having been granted the permission by the FDA to conduct such a compassionate access program, we are currently in this program. The study we are running has registrational quality. If it would be successful it could be the basis for a FDA approval.

When can sufficient data be collected for a possible approval application in the US?

That depends on the rate of enrolment in the currently ongoing trial. At this time, this is not a problem as there are many patients suffering from Covid-19, particularly in the US. If that persists, it would only take us a few more months to get to the point where we would be able to report top-line results from this trial.

How long would it take to get approval after filing?

If you look at Gilead’s Remdesivir, I believe they got emergency authorization from the FDA within weeks after they furnished data. If we get meaningful data, I would expect that the FDA would act in an expedient and collaborative manner. I do not anticipate that we would need ten to twelve months for approval.

What's the probability of Aviptadil getting approval?

The active pharmaceutical ingredient of Aviptadil has been used for a lot of years in different indications. From a safety standpoint we are quite optimistic. From an efficacy standpoint we need more data. I would say the probability at the moment stands at 60 to 70% that we will get the drug approved.

Who finances the ongoing trials?

Relief is paying for the trials. NeuroRx conducts the study on our behalf and we cover all the invoices.

Do you have an agreement with NeuroRx about who receives how much of the profits from Aviptadil? Or is the drug fully owned by Relief?

Aviptadil is our drug.

You are entitled to all revenues it could create?

That is the current situation.

How much do the trials cost?

There are effectively two trials: For the one we are currently running the total budget will be in the range of CHF 7 to 8 mio. The Inhaled study we just got approval to start will probably cost between CHF 10 and 15 mio.

This is total cash burn of around CHF 20 mio. At the beginning of the year, Relief had only CHF 137’000 cash on its balance sheet. How do you finance the expenses?

We have already spent close to CHF 4 mio. on the trials, and we currently have close to CHF 3 mio. on our balance sheet. We have access to a share subscription facility from which we can draw. With the currently high liquidity in our stock we have sufficient access to capital to fund these studies on our own.

How exactly?

We can place authorized share capital in the market. However, if liquidity is available as it happened at various times before, our major shareholder, the private equity firm GEM, allows us to place shares with them at a pre-designed price mechanism that is based on the weighted average stock price. We are not obligated to draw this source of liquidity but can take it and spend it as and when we need it.

Relief has just exchanged a loan by GEM in the amount of CHF 1,7 mio. with 58 mio. shares for a price of CHF 0.033 each. This transaction closed at the end of July, now this share package is worth in excess of CHF 30 mio. Is there any lock-up period for GEM?

We have agreed to convert those notes to equity as we wanted to eliminate this debt from our balance sheet. I have no knowledge of an intent of GEM to sell any of their shares in Relief. They have been with us since 2015 as a faithful long-term shareholder and have supported us for more than five years.

Relief has 2,2 bn shares outstanding. Additionally, there is authorized share capital of 1,1 bn shares, conditional capital of nearly 1 bn shares for bonds and additional 1,8 bn shares for employee benefit plans. However, there are only a handful of employees at the company.

The share benefit plan is not intended solely for the existing employees. It is to give us the possibility to hire additional people and establish further infrastructure as and when we would need it.

What would be your distribution strategy for Aviptadil in case of approval?

We are pragmatic. Aviptadil is aimed for a very targeted costumer base in hospitals. But in any case, we would depend on existing distribution channels in the respective territories. Having said this, we would also be open to offers from interested parties who are willing to value the drug appropriately – especially once we have positive clinical data that convinces the FDA to grant us approval. We will be working pragmatically to find the optimal way to extract the maximum commercial value from the franchise.
Raghuram Selvaraju
Raghuram «Ram» Selvaraju was born in 1978, is a Swiss citizen and, in addition to his position as Chairman of the Board of Directors of Relief Therapeutics, is Managing Director and Senior Healthcare Analyst at the US financial services provider H.C. Wainwright & Co. Selvaraju. He spent a large part of his career in the financial industry as an analyst, but started his career with the former Serono, which is now part of Merck KGaA based in Germany. He holds a bachelor's degree in life sciences and technical writing from Carnegie Mellon University, a master's of science degree in molecular biology from the University of Geneva based on his research in drug development, and holds an M.B.A. in the accelerated one-year program for scientists and engineers at Cornell University.
Mr Market
Warum Anleger beim Überflieger Relief Therapeutics vorsichtig sein sollten
Die Valoren des Biotech-Unternehmens sind seit Anfang Jahr 14'000% gestiegen. Die Hoffnung auf einen Wirkstoff zur Behandlung von Corona-Patienten beflügelt die Fantasie. Die Aktien sind aber ein äusserst riskantes Investment.
Michael Griesdorf 05.08.2020
Mr Market
Gilead überrascht mit positiven Daten zu Covid-19-Medikament
Das Präparat Remdesivir zeigt in wissenschaftlichen Studien Wirkung. Die Aktien des Biotechkonzerns sind nach den jüngsten Avancen nicht mehr günstig. Investoren sollten temporäre Kursrückschläge für Engagements abwarten.
Michael Griesdorf 30.04.2020
Interview
«Roche ist kein Gewinner der Coronapandemie»
Der CEO der Roche-Pharmadivision, Bill Anderson, spricht lieber über die Zukunft als über die Gefahr von Biosimilars. Die Pandemie habe sowohl positive als auch negative Auswirkungen auf Roche.
Michael Griesdorf 27.04.2020

   Kontakt
   AGB und Datenschutz
   Impressum

 

25.04.21 14:48

665 Postings, 525 Tage IneosZulassung Remdesevir , wie gehts weiter ?

So wie ich das interpretiere wird gegen die Zulassung von Remdesevir ( Gilead )
geklagt da seitens FDA nicht alle Regulatorien eingehalten wurden ( Druck durch Trump ? )
Nun wird ja seitens NIH die Vergleichsstudie durchgeführt ( erste Patienten rekrutiert )
zwischen Aviptadil/Remdesevir . Sollte Remdesevir seine Zulassung verlieren sind nur noch
wir da oder ?? Wie seht ihr das ? Habe ich was übersehen oder falsch verstanden ? Allen
noch einen schönen Sonntag und nen fetten grünen Montag !! :-)


https://investorshub.advfn.com/boards/...sg.aspx?message_id=163405853  

26.04.21 06:55

665 Postings, 525 Tage IneosAviptadil :-)

VIRAFIN, AVIPTADIL MAY HELP WITH iMMUNOTHERAPY-INDUCED PNEUMONITIS, AMONG OTHER HEALTH CONCERNS

Pegylated interferon (Peg-IFN) in combination with ribavirin is the standard of care in the treatment of chronic hepatitis C (HCV). Peg-IFN is known to have a number of side effects but severe respiratory complications are uncommon. We report two cases, one of Peg-IFN induced interstitial pneumonitis (IP) and the other of bronchiolitis obliterans organising pneumonia (BOOP) in patients with chronic hepatitis C infection. In general, respiratory complications of Peg-IFN are mild and resolve with withdrawal of Peg-IFN. However, as illustrated in our first case fatal interstitial pneumonitis can occur.

https://pubmed.ncbi.nlm.nih.gov/23813142/

Checkpoint inhibitor-induced pneumonitis (CIP) is characterized clinically by dyspnea, cough and tachypnea. Hypoxia results from a lymphocyte-dominated alveolitis leading to ground glass opacities and consolidations observed by CT scan. Histological findings include lymphocytic infiltrates, granuloma formation and eosinophilic accumulation. In the management of CIP, systemic administration of steroids such as methylprednisolone is the standard therapy. Moreover, CIP in most cases leads to discontinuation of checkpoint inhibitory therapy and steroids limit the therapeutic effect of checkpoint inhibitors resulting in progression of the underlying malignant disease. Therefore, there is a need of other therapeutic options in CIP that ideally could abrogate the alveolar inflammation induced by checkpoint inhibitors without affecting the systemic effect on the immune system. The focus of the present invention is to deliver a solution to that problem by the topic application of VIP (vasoactive intestinal peptide, a peptide of 28 amino acids). A drug for inhalative VIP therapy is commercially available under the name Aviptadil.

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020225246  

26.04.21 10:21

733 Postings, 1069 Tage User88Immerhin

Ein Fortschritt, es geht nicht nach unten bei News.  

27.04.21 14:08

665 Postings, 525 Tage IneosInfo Vergleichsstudie Remdesevir/Aviptadil :-)

27.04.21 16:44

6 Postings, 83 Tage fbo|229327784Prim?rabschluss: Oktober 2022

27.04.21 16:47

6 Postings, 83 Tage fbo|229327784Studienende 10-2022

das ist ja noch eine halbe Ewigkeit wollte ich sagen. Hier ist wohl wirklich extrem Geduld gefragt. 

 

27.04.21 19:28
1

55 Postings, 919 Tage Lerner84Da hat sich das wohl mit COVID erledigt

28.04.21 21:06

665 Postings, 525 Tage Ineoswird immer enger für big Pharma :-)



https://www.prnewswire.com/news-releases/...nd-georgian-ministry-o...

NeuroRx und das georgische Gesundheitsministerium vereinbaren den Start eines Expanded-Access-Programms für ZYESAMI (Aviptadil-Acetat) zur Behandlung von COVID-19-Atemversagen in Georgien

RADNOR, Pa. und TBLISI, Georgien, 28. April 2021 /PRNewswire/ -- NeuroRx gibt heute bekannt, dass es sich mit Dr. Ekaterine Tikaradze, Gesundheitsministerin von Georgien, und anderen hochrangigen Führungskräften getroffen hat, um sofort ein Expanded Access Program (EAP) seines Phase-3-Medikaments ZYESAMI (Aviptadilacetat) für schwerkranke Bürger Georgiens mit COVID-19-Atemversagen einzuleiten.  Das EAP wird in Zusammenarbeit mit Denk Pharma Georgia, Georgiens wichtigstem Pharmahändler, und unter der Schirmherrschaft des Potomac Institute of Policy Studies und des Richard G. Lugar Center for Public Health Research durchgeführt, einer Forschungseinrichtung, die von der U.S. Defense Threat Reduction Agency finanziert und zu Ehren des ehemaligen U.S. Senators Richard G. Lugar benannt wurde, um internationale Forschungsanstrengungen in ihrem Bestreben zu unterstützen, globale Krankheiten zu stoppen.

Das georgische Gesundheitsministerium hat die Genehmigung erteilt, dass das von der US-amerikanischen FDA genehmigte EAP (www.clinicaltrials.gov NCT04453839) unter der Aufsicht des georgischen Gesundheitsministeriums in Georgien und möglicherweise auch in anderen Nachbarländern in der Kaukasusregion durchgeführt werden kann.  

Minister Tikaradze sagte: "Wir in Georgien sind begeistert von der kürzlichen Ankündigung von Dr. Anthony Fauci, dass NeuroRx und ZYESAMI als Industriepartner an der NIH ACTIV3b Studie teilnehmen werden. Wir freuen uns, ein Expanded Access Programm für ZYESAMI in Georgien unter unserer Aufsicht mit der Beteiligung von Denk Pharma Georgia und dem Lugar Center for Public Health Research zu initiieren."

"Während sich die Welt auf einen weiteren Anstieg von COVID-19 und seinen Varianten vorbereitet, fühlen wir uns bei NeuroRx geehrt, vom georgischen Gesundheitsministerium als Teil ihrer Strategie zum Schutz ihrer Bürger ausgewählt worden zu sein", sagte Prof. Jonathan Javitt, CEO und Chairman von NeuroRx. "In den kommenden Wochen freuen wir uns darauf, breitere Programme anzukündigen, die sowohl Immunisierungsstrategien als auch COVID-19-Therapeutika beinhalten, um den Menschen in der Kaukasusregion zu dienen."

Ein Plan bringt Stabilität. Auf festem Boden lässt sich Erfolg aufbauen.
Es gibt nichts Gutes oder Schlechtes, nur das Denken macht es so.
Immer besser werden wollen- in allem, was wir tun.

 

28.04.21 21:46

665 Postings, 525 Tage Ineoseiner geht noch :-)

SALT LAKE CITY (ABC4) – Researchers at Intermountain Healthcare are at the forefront of a national study that aims to help COVID-19 patients with life-threatening cases of the virus, including those with acute respiratory failure.
It’s part of a new, multi-center National Institutes of Health study that is being launched across the nation to test the safety and efficacy of therapeutics for these patients.
Can my employer legally ask if I received the COVID-19 vaccine?
The randomized trial will test two therapeutic agents – Zyesami and remdesivir – to determine how well they work and if they are safe for hospitalized COVID-19 patients who are experiencing Acute Respiratory Distress Syndrome.
ARDS is a life-threatening condition in which the lungs are severely inflamed and may be unable to maintain sufficient oxygen in the blood, according to Intermountain Healthcare.
This is the first trial to focus entirely on patients with ARDS, which is the most severe phase of COVID-19 illness, health experts explain.
How long does protection from COVID-19 vaccines last?
Samuel Brown, MD, MS, critical care physician and researcher at Intermountain Healthcare in Salt Lake City, is the principal investigator of the Phase 3 trial, and is coordinating with scientists at study sites throughout the nation.
Dr. Brown will provide more details about this study during a 10:30 a.m. breifing, which you can watch above.
Categories: Coronavirus Updates, Local News, Top Stories, Wasatch Front
Tags: Intermountain Healthcare
ABC4 Utah  

30.04.21 12:10
1

35 Postings, 314 Tage greenpeaceGeduld & Hoffnung schwindet


Bin nun seit Juli 2020 investiert und verliere langsam aber sicher meine Hoffnung. Der Gedanke, dass ich mir das
ganze Jahr hätte sparen können und trotzdem einen ähnlichen EP hätte, nagt an meinem Gemüt.
Zusammenfassend:
Endpunkte der Studie sind erreicht, Nebenwirkung: Durchfall!!! und die EUA ist nirgends...
Weshalb zum Teufel wird gewartet?

Danke @Ineos für den interessanten Bericht bezüglich der Beziehung zwischen FDA und Pharmaindustrie - betrachten tue ich die ganze Geschichte danach auch ein wenig anders. Am Ende des Tages zählt offensichtlich nur KOHLE, nicht Menschenleben! - ebenfalls bei unserer  scheinheiligen "Gesundheitsbehörde"  

02.05.21 00:19

25 Postings, 446 Tage FNATICservus greenpeace

Soweit ich da bis jetzt gesehen habe, ist das ja nur die Phase 1 Studie die abgeschlossen wurde, oder irre ich mich?  Dann ist natürlich verständlich dass sich da noch nicht viel tut. In der Regel warten die meiste Investoren die Ph2 studienergebnisse ab, bevor investiert wird.  

02.05.21 08:45

733 Postings, 1069 Tage User88Ich habe 'mal eine Frage an die Experten

Wie ist dass eigentlich mit den Antikörpern, die sich nach der Infektion natürlich
gebildet haben, werden die beim Impfen zerstört oder nicht?
Wie lange hält die Impfung und was kommt danach?

Ich hatte Corona, habe Antikörper und soll mich jetzt Impfen lassen.  

02.05.21 09:58

40 Postings, 1025 Tage DagiorNach der Impfung ist vor der Impfung

So wie sich die Anzeichen verdichten, kommen die geimpften nicht darum herum sich eventuell das ganze Leben impfen zu lassen... Oder zumindest einige Jahre. Sollte jeder für sich entscheiden  

02.05.21 11:07

665 Postings, 525 Tage Ineosinvestiert den Kurs zu drücken :-)

30.04.2021 17:31:39 0.206 8'000
30.04.2021 17:31:39 0.206 1'001
30.04.2021 17:31:39 0.206 37'885
30.04.2021 17:31:39 0.206 227'949
30.04.2021 17:31:39 0.206 77'264
30.04.2021 17:31:39 0.206 50'000
30.04.2021 17:31:39 0.206 102'210
30.04.2021 17:31:39 0.206 41'700
30.04.2021 17:31:39 0.206 5'000
30.04.2021 17:31:39 0.206 6'200
30.04.2021 17:31:39 0.206 100'000
30.04.2021 17:31:39 0.206 1'203
30.04.2021 17:31:39 0.206 80'000
30.04.2021 17:31:39 0.206 10'000
30.04.2021 17:31:39 0.206 217'822
30.04.2021 17:31:39 0.206 3'500
30.04.2021 17:31:39 0.206 192'604
30.04.2021 17:31:39 0.206 202'224
30.04.2021 17:31:39 0.206 20'729
30.04.2021 17:31:39 0.206 31'341
30.04.2021 17:31:39 0.206 68'274
30.04.2021 17:31:39 0.206 23'094
30.04.2021 17:31:39 0.206 1'010
30.04.2021 17:31:39 0.206 7'879
30.04.2021 17:31:39 0.206 601
30.04.2021 17:31:39 0.206 25'000
30.04.2021 17:31:39 0.206 11'657
30.04.2021 17:31:39 0.206 12'742
30.04.2021 17:31:39 0.206 45'865
30.04.2021 17:31:39 0.206 17'541
30.04.2021 17:31:39 0.206 8'750
30.04.2021 17:31:39 0.206 25'498
30.04.2021 17:31:39 0.206 26'250
30.04.2021 17:31:39 0.206 17'882
30.04.2021 17:31:39 0.206 8'214
30.04.2021 17:31:39 0.206 19'000
30.04.2021 17:31:39 0.206 20'730
30.04.2021 17:31:39 0.206 30'000
30.04.2021 17:31:39 0.206 2'350
30.04.2021 17:31:39 0.206 20'730
30.04.2021 17:31:39 0.206 20'729
30.04.2021 17:31:39 0.206 23'513
30.04.2021 17:31:39 0.206 131'251
30.04.2021 17:31:39 0.206 3'498
30.04.2021 17:31:39 0.206 1'561
30.04.2021 17:31:39 0.206 3'235
30.04.2021 17:31:39 0.206 5'000
30.04.2021 17:31:39 0.206 32'000
30.04.2021 17:31:39 0.206 13'426
30.04.2021 17:31:39 0.206 1
30.04.2021 17:31:39 0.206 6
30.04.2021 17:31:39 0.206 13'019
30.04.2021 17:31:39 0.206 60'235
30.04.2021 17:31:39 0.206 862
30.04.2021 17:31:39 0.206 9'704
30.04.2021 17:31:39 0.206 13'397
30.04.2021 17:31:39 0.206 82'553
30.04.2021 17:31:39 0.206 4'618
30.04.2021 17:31:39 0.206 146'056
30.04.2021 17:31:39 0.206 5'335
30.04.2021 17:31:39 0.206 272
30.04.2021 17:31:39 0.206 98'337
30.04.2021 17:31:39 0.206 21'385
30.04.2021 17:31:39 0.206 41'691
30.04.2021 17:19:59 0.207 5'878
30.04.2021 17:19:47 0.209 23'323
30.04.2021 17:19:47 0.209 26'277
30.04.2021 17:19:47 0.209 20'000
30.04.2021 17:19:47 0.208 5'000
30.04.2021 17:19:45 0.207 18'969
30.04.2021 17:19:40 0.207 32'081
30.04.2021 17:19:40 0.207 13'384
30.04.2021 17:19:40 0.207 61'616
30.04.2021 17:19:40 0.207 120'245
30.04.2021 17:19:35 0.207 7'655
30.04.2021 17:19:35 0.210 195'460
30.04.2021 17:19:35 0.210 4'600
30.04.2021 17:19:35 0.210 100'000
30.04.2021 17:19:35 0.210 9'572
30.04.2021 17:19:35 0.209 7'594
30.04.2021 17:19:35 0.209 20'000
30.04.2021 17:19:35 0.209 8'192
30.04.2021 17:19:35 0.209 30'720
30.04.2021 17:19:35 0.208 30'040
30.04.2021 17:19:35 0.208 67'191
30.04.2021 17:19:35 0.208 190'887  

Seite: 1 | ... | 48 | 49 | 50 |
| 52 | 53 | 54 | ... | 55   
   Antwort einfügen - nach oben
Werbung
finanzen.net Brokerage
finanzen.net Zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln